Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.41 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.41 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.41 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340012 | 0.85 | KDM4E (0.45) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1711419 | 0.82 | PIM1 (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL319710 | 0.82 | CTSA (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL29357675 | 0.82 | KDM4E (0.76) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL70765 | 0.82 | KDM4E (0.76) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1711547 | 0.81 | KDM4E (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL319346 | 0.81 | KDM4E (0.52) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL18259555 | 0.81 | MAPT (0.52) | PIM1PIM3PIM2 | |
| SCHEMBL1711736 | 0.80 | PIM1 (0.47) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL143651 | 0.80 | KDM4E (0.73) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743269-B1 | PIM KINASE INHIBITOR, PREPARATION METHOD AND USE THEREOF IN DRUG PREPARATION | JIKAI BIOSCIENCES INC (CN) | 2018-09-26 | — | — | EP | disclosed |
| US-9802918-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802918-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802918-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| EP-2743271-B1 | PIM KINASE INHIBITORS AND PREPARATION METHOD AND USE IN MEDICINAL MANUFACTURE THEREOF | JIKAI BIOSCIENCES INC (CN) | 2017-05-31 | — | — | EP | disclosed |
| US-9540347-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540347-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | KDM4E 673/4885ALOX15 4708/4885TSHR 3329/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | KDM4E 673/4885ALOX15 4708/4885TSHR 3329/4885 |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | KDM4E 752/4885ALOX15 4720/4885TSHR 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.